Table 3

Projected Lifetime Costs, QALY, and Cost-Effectiveness Ratios

Lifetime Costs ($)LY or QALYICER ($/QALY)Probability <$50,000 per QALY (%)Probability <$150,000 per QALY (%)
TAVRSAVRΔTAVRSAVRΔ
Base case207,478189,62917,8494.1493.8250.32455,09040.390.0
Subgroup analyses
 IF access, n = 627202,799191,47911,3204.1013.8870.21452,89742.675.2
 Non-IF access, n = 120229,487181,78447,7034.3213.5610.76062,76727.683.1
 STS PROM
 ≥7, n = 376190,957183,74972083.4493.4170.032225,25025.444.5
 <7, n = 371222,812196,84225,9704.8084.2850.52349,65646.692.8
 Male, n = 394196,144186,3979,7473.9113.8140.09899,45926.749.7
 Female, n = 353219,025194,35424,6714.3773.8740.50249,14550.094.0
 Age, yrs
 ≥85, n = 377176,420165,97710,4433.0602.8480.21149,49350.180.2
 <85, n = 370237,939215,02222,9175.2234.8520.37061,93831.881.6
Sensitivity/scenario analyses
 Effectiveness = LY207,478189,62917,8495.4695.0550.41443,11463.992.1
 Discount rate
 0%230,921210,43320,4884.8784.4780.40051,22047.090.3
 5%195,540178,92216,6183.7763.4880.28857,70135.890.0
 Long-term hazard ratio = 0.86215,243189,62925,6154.3903.8250.56645,25663.799.3
 No difference in 1 month QOL207,478189,62917,8494.1383.8320.30658,33033.388.6
 No costs in added LY116,717106,11310,6044.1493.8250.32432,72870.891.3

ICER = incremental cost-effectiveness ratio; IF = iliofemoral; LY = life-year; QALY = quality-adjusted life-year; QOL = quality of life; STS PROM = Society of Thoracic Surgeons predicted risk of mortality; other abbreviations as in Table 1.